Compare Taiko Pharmaceutical Co., Ltd. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 5.99%
- The company has been able to generate a Return on Equity (avg) of 5.99% signifying low profitability per unit of shareholders funds
2
Weak Long Term Fundamental Strength with a -43.41% CAGR growth in Operating Profits over the last 5 years
3
Poor long term growth as Net Sales has grown by an annual rate of -21.72% and Operating profit at -43.41% over the last 5 years
4
Flat results in Jun 26
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 13,824 Million (Small Cap)
32.00
NA
0.00%
-0.41
5.06%
1.67
Revenue and Profits:
Net Sales:
1,720 Million
(Quarterly Results - Jun 2026)
Net Profit:
139 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.1%
0%
-4.1%
6 Months
-15.18%
0%
-15.18%
1 Year
-16.29%
0%
-16.29%
2 Years
-34.44%
0%
-34.44%
3 Years
-27.4%
0%
-27.4%
4 Years
-57.38%
0%
-57.38%
5 Years
-73.26%
0%
-73.26%
Taiko Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-21.72%
EBIT Growth (5y)
-43.41%
EBIT to Interest (avg)
-178.85
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.38
Sales to Capital Employed (avg)
0.64
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
17.96%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.17%
ROE (avg)
5.99%
Valuation key factors
Factor
Value
P/E Ratio
32
Industry P/E
Price to Book Value
1.61
EV to EBIT
31.25
EV to EBITDA
16.65
EV to Capital Employed
2.04
EV to Sales
1.61
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
6.53%
ROE (Latest)
5.06%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
1,720.00
916.00
87.77%
Operating Profit (PBDIT) excl Other Income
190.00
-24.00
891.67%
Interest
1.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
139.00
-95.00
246.32%
Operating Profit Margin (Excl OI)
66.90%
-105.90%
17.28%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 87.77% vs -57.75% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 246.32% vs -137.40% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
6,397.00
6,292.00
1.67%
Operating Profit (PBDIT) excl Other Income
724.00
886.00
-18.28%
Interest
5.00
8.00
-37.50%
Exceptional Items
146.00
-131.00
211.45%
Consolidate Net Profit
923.00
898.00
2.78%
Operating Profit Margin (Excl OI)
71.80%
100.10%
-2.83%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 1.67% vs 2.81% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 2.78% vs 124.87% in Dec 2024
About Taiko Pharmaceutical Co., Ltd. 
Taiko Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






